Sign In
Buy GILD
$125.16
+0.110 (+0.0880%)
At Close: Jun 24, 2026
Gilead stock falls after disappointing lung cancer study results
11:57am, Monday, 22'nd Jan 2024
Gilead will discuss the results with regulators and identify whether certain lung cancer patients may still benefit from the drug, known as Trodelvy.
Gilead says its Trodelvy disappointed in a late-stage cancer trial
09:41am, Monday, 22'nd Jan 2024
Gilead Sciences Inc (NASDAQ: GILD) says its drug conjugate Trodelvy disappointed in a late-stage cancer trial. Shares of the biotech firm opened about 10% down today.
Gilead's stock tumbles toward biggest selloff in more than 9 years after lung cancer treatment trial disappoints
08:43am, Monday, 22'nd Jan 2024
Shares of Gilead Sciences Inc. GILD, +1.03% tumbled 10.9% beating in premarket trading Monday, to pullback from an 11-month high, after the biotechnology company disappointing trial results of its lun
Gilead says Trodelvy fails to meet primary goal in 2nd-line lung cancer trial
08:35am, Monday, 22'nd Jan 2024
Gilead Sciences on Monday said a late-stage trial of its antibody-drug conjugate Trodelvy failed to show that it significantly improved survival for previously treated patients with advanced non-small
Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts
07:06pm, Wednesday, 17'th Jan 2024
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $86.48, denoting a +0.57% change from the preceding trading day.
Final Trades: Verizon, Abbvie, Gilead Sciences and Arch Capital Group
01:39pm, Wednesday, 17'th Jan 2024
Jenny Harrington, Gilman Hill Asset Management CEO, Jim Lebenthal, chief equity strategist at Cerity Partners, Joe Terranova, senior managing director at Virtus Investment Partners, and Rob Sechan, ma
Can AI and a supercomputer beat the markets? This is one of the hedge funds trying to find out.
12:47pm, Wednesday, 17'th Jan 2024
In a downtown Toronto skyscraper one block away from the Hockey Hall of Fame, a small hedge fund is hoping it has found an edge in financial markets. Castle Ridge Asset Management is betting on Wallac
Stocks This Week: Buy The Biotech Stocks: Amgen And Gilead
06:00am, Tuesday, 16'th Jan 2024
Two sets of reliable stock market cycles have topped. Technically, the market does not appear as weak as expected.
Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know
07:33pm, Thursday, 11'th Jan 2024
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $85.39, denoting a +1.05% change from the preceding trading day.
Top Stock Picks for 2024: Gilead Sciences
01:03pm, Thursday, 11'th Jan 2024
Every day for the next three weeks, we're going to highlight one of Schaeffer's top 12 picks for 2024.
Gilead's Quiet Revolution: Is GILD the Next Big Stock to Soar?
02:14pm, Wednesday, 10'th Jan 2024
Biotechnology company Gilead Sciences (NASDAQ: GILD ) wasn't a “Magnificent Seven” company or a darling of the financial markets in 2023. Yet, GILD stock deserves a long-overdue rally in 2024.
U.S. Wide-Moat Stocks On Sale - The January 2024 Heat Map
01:17pm, Wednesday, 10'th Jan 2024
Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating).
My Top 3 YARP Stocks Right Now (Yield At A Reasonable Price)
10:58am, Wednesday, 10'th Jan 2024
This article introduces a dividend stock selection process called YARP (Yield At a Reasonable Price) that prioritizes risk management and total return. YARP aims to identify stocks with historically h
3 health care stocks off to strong starts in 2024
07:01am, Wednesday, 10'th Jan 2024
Up 2% five trading days into the new year, global health care stocks have already matched their return for all of 2023. It's very early, but the sector has outpaced all other 10 economic groups since
Gilead CEO On 2024 drug pipeline: Expect results from around two dozen clinical trials
10:20am, Monday, 08'th Jan 2024
Gilead Sciences CEO Daniel O'Day joins 'Squawk Box' to discuss Gilead's drug pipeline in 2024, the company's HIV treatment, breast cancer drug, and more.
